AMA grants procedure codes for pigmented lesion assay for melanoma

DermTech has reported that the AMA has granted the company category 1, tier 2 molecular pathology procedure codes related to its proprietary test for the detection of melanoma-related gene expression.

The common procedural terminology coding is for two primary genes included in the pigmented lesion assay, DermTech’s non-invasive biopsy and gene expression test for skin cancer, according to a news release.

The genes will be added to the approved list for CPT code 81401, as maintained by the AMA and published July 1.

Multiple clinical studies demonstrating the clinical validity and utility of the test as well as support from dermatology societies including the American Academy of Dermatology were used to support the application, DermTech reported.

"We thank the AMA, the American Academy of Dermatology, the College of American Pathologists, the Society for Investigative Dermatology, and others that unanimously supported our application,” John Dobak, MD, CEO of DermTech, stated in the release.

 

Reference: www.dermtech.com

DermTech has reported that the AMA has granted the company category 1, tier 2 molecular pathology procedure codes related to its proprietary test for the detection of melanoma-related gene expression.

The common procedural terminology coding is for two primary genes included in the pigmented lesion assay, DermTech’s non-invasive biopsy and gene expression test for skin cancer, according to a news release.

The genes will be added to the approved list for CPT code 81401, as maintained by the AMA and published July 1.

Multiple clinical studies demonstrating the clinical validity and utility of the test as well as support from dermatology societies including the American Academy of Dermatology were used to support the application, DermTech reported.

"We thank the AMA, the American Academy of Dermatology, the College of American Pathologists, the Society for Investigative Dermatology, and others that unanimously supported our application,” John Dobak, MD, CEO of DermTech, stated in the release.

 

Reference: www.dermtech.com